Skip to content
Search

Latest Stories

Boots to offer £42k FTE base salary to newly-qualified pharmacists

Boots UK will offer a staring salary of £42,000 per annum to newly qualified pharmacists joining the pharmacy chain.

The company also revealed that "in addition, any existing pharmacists in the bargaining unit currently receiving less than £43k.”


The newly announced hike in the salary -- following an agreement reached between the multiple and and the Pharmacist Defence Association -- will be effective from 1 August 2022.

“This enhanced offer for Newly Qualified Pharmacists and further investment in those in the early stages of their careers at Boots is a key part of our commitments to pharmacists,” the company said.

Boots and PDA Union also announced in a joint statement that they will conduct a further formal review of all pharmacists’ pay in accordance with the collective agreement, effective from 1 November 2022.

“Those receiving this adjustment to £43k will remain part of the November 2022 pay review. Details of the November 2022 pay review will be shared in due course once this year’s pay negotiations have taken place.”

Newly-qualified Boots pharmacists' salary in past 10 years

“When the PDA Union explained to pharmacists the potential benefits of union recognition at Boots before the ballots, a significant issue identified was that NQ pharmacists starting salaries had been suppressed for many years. In the entire 10 years before union recognition, NQ starting salaries had increased by just 3 per cent (2007: £33,000 to 2018: £34,000),” said PDA.

"For the last 10 years, salaries for newly-qualified Boots pharmacists have remained almost static."

In 2007, Boots newly qualified pharmacist were offered £33,000; equivalent salary in 2017, taking into account inflation: Circa £43,527 and actual Boots newly qualified pharmacist salary 2017/18: £34,000.

“In addition, hundreds of Boots pharmacists have been disadvantaged by market-based pay which was introduced in 2014. Pharmacists’ salaries are based on undisclosed “market data” from an unspecified source,” said PDA.

“We think pharmacists should be told exactly how their salaries are being determined, and have the opportunity to negotiate better ones.”

“However, in the four years since pharmacists secured the rights to collective bargaining, these starting rates have increased by 23.5% (2018: £34,000 to 2022: £42,000). Union negotiators have also agreed with Boots that any increase to NQ pharmacist salaries cannot place NQ pharmacists on higher salaries than established colleagues, something that was not publicly guaranteed when the company decided pay rates by itself.”

While the PDA Union believes that the NQ pharmacist rates increase will significantly increase income for some lower-paid pharmacists in the bargaining unit, others will see no increase as a result of this.

The PDA Union, therefore, recognises that these increases do have an impact on differentials, closing the pay gap between brand-new pharmacists and their more experienced colleagues.

Those who have not benefitted significantly or at all under this proposal in the forthcoming pay review will be on the Union's priority.

The Union will also seek to ensure members at Boots are actively encouraged to provide their opinions to the union negotiators before the claim is finalised.

More For You

Beware of wage theft: PDA warns locums

Booking terms should clearly outline not only the dates of work, shift times, and rate of pay but also the required notice period

Getty Images

PDA warns locum pharmacists of ‘wage theft’ risk

The Pharmacists' Defence Association (PDA) has advised locum pharmacists to check booking terms carefully before accepting shifts, warning of the risk of ‘wage theft’ and delayed payments.

According to the union, locum members have reported being owed significant unpaid fees for services provided, with some pharmacists claiming debts exceeding £20,000."

Keep ReadingShow less
UK "medicines market is fundamentally broken

Drug manufacturers have seen a sharp rise in the money they have to pay the NHS

Pic credit: iStock

UK "medicines market is fundamentally broken,” says industry leadership group

The UK government have been accused of putting off investors in drug manufacturing over the “unsustainable levy” companies are having to pay the NHS.

Industry leaders have warned that the government’s growth plan will not succeed unless ministers commit to fixing a scheme which now requires companies to make record payments up to a quarter to a third (23.5 per cent-35.6 per cent) of a company’s revenue from sales of branded medicines to the NHS.

Keep ReadingShow less
Listeria outbreak: Cool Delight Desserts products removed from health care setting

The bacteria were detected in chocolate and vanilla and strawberry and vanilla flavoured mousse.

Cool Delight Desserts

3 deaths linked to listeria outbreak; NHS staff advised to withdraw Cool Delight Desserts products

NHS staff have been advised to remove all Cool Delight Desserts products from service and sales as a precautionary measure following the death of three people linked to a listeria outbreak.

The UK Health Security Agency (UKHSA) and Food Standards Agency (FSA) are investigating five cases of Listeria monocytogenes infection linked to the same strain of bacteria found in mousses supplied to NHS hospitals and care homes.

Keep ReadingShow less
Impact of National Insurance rise on community pharmacies.

Pharmacies are faced with higher NI payments

Pic credit: Istock

Pharmacies to pay higher national insurance contributions after MPs refuse to back amendments to bill


Community pharmacies are faced with paying the higher rate of national insurance contributions that come into force next month after MPs on Wednesday (19) rejected amendments to a bill that was approved by the House of Lords.

Keep ReadingShow less
Novo Nordisk regains ABPI membership after two-year suspension

Novo Nordisk was suspended in March 2023 for sponsoring pharmacy weight management training courses.

Image Credit: Novo Nordisk

Novo Nordisk’s ABPI suspension lifted after two years

Novo Nordisk has regained full membership of the Association of the British Pharmaceutical Industry (ABPI) after a two-year suspension due to serious breaches of the ABPI Code of Practice.

The reinstatement follows rigorous audits of the company’s compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA).

Keep ReadingShow less